Research and Markets: PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/s84x32/pharmapoint) has announced the addition of the "PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023" report to their offering.

Novel Drug and Biosimilar Launches to Transform Rheumatoid Arthritis Treatment Market Dynamics by 2023

This report provides annualized Rheumatoid Arthritis (RA) market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023. The key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the RA biologics and biosimilars markets.

The global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 2.1%.

The report states that of the 10 major pharmaceutical markets (the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China, and India), the US boasts the largest RA treatment space, with a 67% share in 2013. The country will maintain its leading position by the end of 2023, despite its share declining slightly to 65%.

The authors believes that the RA treatment market expansion over the coming decade will be driven by increased RA prevalence, as well as the anticipated launches of novel drugs. These products include three interleukin-6 inhibitors, four biologics novel to the RA market, four Janus kinase (JAK) inhibitors, and numerous biosimilars.

Heather Leach, Ph.D., The Analyst covering Immunology, says: Drugs with novel mechanisms of action, including biologics and small molecules, are welcome additions to the RA therapeutics market. However, this arena will become increasingly crowded over the next decade.

RA is an attractive therapy area for pharmaceutical companies as it is dominated by expensive biologics, and oral JAK inhibitors entering the market are expected to be priced only at a slight discount. Perhaps the most anticipated event in the RA space is the addition of biosimilars, which are assumed to be priced at a 30% discount to the reference product.

However, Leach adds that while the launch of biosimilars will provide a less expensive therapy option for patients, their lack of regulatory guidelines will delay their availability in a number of regions.

Furthermore, these alternative products are expected to steal significant patient share and cut into the profits of major RA treatment brands, such as Amgen/Pfizer/Takeda's Enbrel, AbbVie's Humira, and Bristol Myers Squibb/Ono's Orencia. This will impact negatively on future revenue growth for this treatment area, the analyst concludes.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Etiology and Pathophysiology

3.2 Symptoms

3.3 Prognosis

3.4 Quality of Life

4 Epidemiology

5 Disease Management

6 Competitive Assessment

6.1 Overview

6.2 Product Profiles - Major Brands

6.2.1 Enbrel (etanercept)

6.2.2 Humira (adalimumab)

6.2.3 Remicade (infliximab)

6.2.4 Simponi (golimumab)

6.2.5 Cimzia (certolizumab pegol)

6.2.6 Orencia (abatacept)

6.2.7 Actemra/RoActemra (tocilizumab)

6.2.8 Rituxan/MabThera (rituximab)

6.2.9 Inflectra/Remsima (infliximab biosimilar)

6.2.10 Xeljanz (tofacitinib)

6.2.11 Iguratimod/T-614

6.2.12 Methotrexate (Numerous Brands)

6.3 Biosimilars

6.3.1 Introduction

6.3.2 Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases

6.3.3 Biosimilars in the Immunology Community

6.3.4 By the Numbers: Biosimilars in Development

6.3.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry

6.3.6 Uptake of Biosimilars for RA is Expected to Vary by Market

6.3.7 Biosimilars' Forecast

6.4 Other Therapies

7 Unmet Need and Opportunity

8 Pipeline Assessment

8.1 Overview

8.2 Clinical Trial Mapping

8.3 Promising Drugs in Clinical Development

8.3.1 Sarilumab

8.3.2 Sirukumab

8.3.3 Clazakizumab

8.3.4 Cosentyx (secukinumab)

8.3.5 Tregalizumab

8.3.6 Mavrilimumab

8.3.7 Denosumab (Prolia/Xgeva)

8.3.8 Baricitinib

8.3.9 Peficitinib

8.3.10 Decernotinib

8.3.11 Filgotinib

8.3.12 Masitinib

8.3.13 RAVAX

8.4 Other Drugs in Development

9 Current and Future Players

10 Market Outlook

11 Appendix

Companies Mentioned

  • AbbVie
  • Pfizer
  • Amgen
  • Johnson & Johnson
  • Eli Lilly
  • Bristol-Myers Squibb
  • UCB
  • Roche
  • GlaxoSmithKline
  • Novartis
  • Sanofi
  • AstraZeneca- MedImmune
  • Astellas
  • Vertex
  • Daiichi Sankyo

For more information visit http://www.researchandmarkets.com/research/s84x32/pharmapoint

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders